SIGLEC7

Across TCGA pan-cancer cohorts, SIGLEC7 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SIGLEC7 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher SIGLEC7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SIGLEC7 expression acts as an unfavorable survival marker.

THYM, HNSC, and KICH are the cancer types where SIGLEC7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
HNSC	DFS	Median	All	0.087	0.710	<.001	24	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
ESCA	OS	Median	All	0.080	0.701	<.001	12	view →
COAD	DFS	Median	IV	0.084	0.494	<.001	12	view →
BLCA	DFS	Median	All	0.261	0.627	.046	6	view →
SKCM	OS	Median	IV	0.415	0.861	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SIGLEC7–THYM (OS)

Open the THYM breakdown →